Compare HOLX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLX | UTHR |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 20.3B |
| IPO Year | 1990 | 1999 |
| Metric | HOLX | UTHR |
|---|---|---|
| Price | $74.91 | $489.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | $79.64 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 3.0M | 424.3K |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | 2.49 | ★ 26.38 |
| Revenue | ★ $4,100,500,000.00 | $3,128,400,000.00 |
| Revenue This Year | $6.69 | $13.64 |
| Revenue Next Year | $5.74 | $5.78 |
| P/E Ratio | $30.11 | ★ $18.55 |
| Revenue Growth | 1.74 | ★ 13.50 |
| 52 Week Low | $51.90 | $266.98 |
| 52 Week High | $80.31 | $492.62 |
| Indicator | HOLX | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 67.93 | 68.10 |
| Support Level | $74.55 | $470.13 |
| Resistance Level | $75.12 | $492.62 |
| Average True Range (ATR) | 0.28 | 10.72 |
| MACD | -0.14 | -0.53 |
| Stochastic Oscillator | 78.92 | 89.55 |
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.